; and (ix) the extent to which the Centers for Medicare & Medicaid Services has implemented the pharmacy performance reporting requirements of section 423.514(a)(5) of title 42, Code of Federal Regulations, the extent to which PDP sponsors or MA organizations (or pharmacy benefit managers acting on their behalf) comply with such provision, and the extent to which the Centers for Medicare & Medicaid Services has sought enforcement. (B) OIG reports (i) Report on initial findings Not later than December 31, 2024, the Inspector General shall submit a report to Congress outlining, to the extent practicable, a status update on the study under subparagraph (A), together with initial findings with respect to the issues included under such study. Such report may include an analysis of barriers to accessing any of the information required under such study, along with recommendations for addressing such barriers. Such report may also include recommendations for the effective implementation of the requirements enacted under this subsection as well as existing regulations, including section 423.514(a)(5) of title 42, Code of Federal Regulations, along with other recommendations, as determined appropriate by the Inspector General. (ii) Interim report Not later than July 31, 2025, the Inspector General shall submit to Congress an interim report on the study under subparagraph (A), including additional recommendations for the implementation of the requirements enacted under this subsection as well as under existing regulations, including section 423.514(a)(5) of title 42, Code of Federal Regulations. (iii) Final report Not later than December 31, 2025, the Inspector General shall submit to Congress a final report on the study under subparagraph (A), together with additional recommendations, as determined appropriate by the Inspector General. (4) Nonapplication of paperwork reduction act Chapter 35 of title 44, United States Code, shall not apply to any data collection undertaken by the Secretary under this paragraph. . (b)